ArticleNeurochemical research2026
Metabolomics and Proteomics Analyses Reveal the Protective Effect of Crocetin Against Depressive-Like Behaviors Mice.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Depression is a common neuropsychiatric disorder, and our previous study revealed that crocetin has antidepressant effects, while the antidepressant mechanism of crocetin is still unknown. This study aimed to probe the antidepressant mechanism of crocetin in chronic unpredictable mild stress (CUMS) induced depressive-like behaviors mice. The hippocampus was collected for metabolomic analyses using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). The ileum was collected for proteomics analyses.The results revealed that crocetin treatment could significantly improve CUMS-induced depression. Metabolic showed that crocetin-treated suggestively altered the metabolite levels in the hippocampus of depressive-like mice. In total, 92 nominal differential abundant metabolites including 37 nominally upregulated and 55 nominally downregulated metabolites, were observed between CUMS and crocetin-treated groups. These differential metabolites were suggestively enriched in the pathway of glycerophospholipid metabolism and oxidative phosphorylation. Crocetin also significantly altered protein synthesized in the ileum of depressive-like behaviors mice. In total, 419 proteins were differentially regulated, including 231 nominally upregulated and 188 nominally downregulated proteins. These differential proteins were significantly enriched in the pathway of retinol metabolism and steroid hormone biosynthesis, and suggestively enriched in the pathway of inflammation-mediated transient receptor potential (TRP) channel, arachidonic acid metabolism, linoleic acid metabolism, and serotonergic synapse. Based on omics analysis, we have formulated a hypothesis for further verification: crocetin significantly affect the lipid metabolism due to its anti-inflammatory and antioxidant activities, especially glycerophospholipid metabolism in the body, thereby exerting an antidepressant effect. These effects may be closely related to the regulatory role of crocetin in the inflammatory state of the ileum. This study demonstrates that multi-omics analysis can provide new insights into the mechanism of drug antidepressant effects.
Indexed as
Identifiers
42640500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.